About the Authors
- Philipp Heissig
-
Contributed equally to this work with: Philipp Heissig, Waldemar Schrimpf
Affiliation Pharmaceutical Biotechnology, Department of Pharmacy and Center for NanoScience (CeNS), University of Munich (LMU), München, Germany
- Waldemar Schrimpf
-
Contributed equally to this work with: Philipp Heissig, Waldemar Schrimpf
Affiliation Physical Chemistry, Department of Chemistry and Center for NanoScience (CeNS), University of Munich (LMU), München, Germany
- Philipp Hadwiger
-
Affiliation Axolabs GmbH, Kulmbach, Germany
- Ernst Wagner
-
* E-mail: don.lamb@cup.uni-muenchen.de (DCL); ernst.wagner@cup.uni-muenchen.de (EW)
Affiliation Pharmaceutical Biotechnology, Department of Pharmacy and Center for NanoScience (CeNS), University of Munich (LMU), München, Germany
- Don C. Lamb
-
* E-mail: don.lamb@cup.uni-muenchen.de (DCL); ernst.wagner@cup.uni-muenchen.de (EW)
Affiliation Physical Chemistry, Department of Chemistry and Center for NanoScience (CeNS), University of Munich (LMU), München, Germany
Competing Interests
Beyond PHa being an employee of Axolabs, there are no other competing interests for any of the authors and the affiliation of PHa with Axolabs does not alter our adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceptualization: P. Heissig WS P. Hadwiger EW DCL. Formal analysis: WS. Funding acquisition: DCL EW. Investigation: P. Heissig WS. Resources: DCL EW. Supervision: DCL EW. Writing – original draft: P. Heissig WS P. Hadwiger EW DCL.